<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1543">
  <stage>Registered</stage>
  <submitdate>2/05/2007</submitdate>
  <approvaldate>2/05/2007</approvaldate>
  <nctid>NCT00469456</nctid>
  <trial_identification>
    <studytitle>Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy of Memantine on Functional Communication in Patients With Alzheimer's Disease (AD)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MEM-MD-71</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Memantine
Treatment: drugs - placebo

Active Comparator: 1 - Memantine 20mg (10mg twice daily) oral administration for 12 weeks

Placebo Comparator: 2 - Placebo oral administration twice daily for 12 weeks


Treatment: drugs: Memantine
Memantine 20mg (10mg twice daily) oral administration for 12 weeks

Treatment: drugs: placebo
Placebo oral administration twice daily for 12 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change From Baseline in Functional Linguistic Communication Inventory (FLCI) at Week 12</outcome>
      <timepoint>Baseline to Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS) [Total Score of Social Communication and Communication of Basic Needs Subscores] at Week 12</outcome>
      <timepoint>Baseline to Week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male and female outpatients, 50 years or older, native English speakers, meeting
             National Institute of Neurological and Communicative Disorders and Stroke--Alzheimer's
             Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD with
             a Mini Mental State Examination (MMSE) score of 10 to 19 at Screening and Baseline</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Current Diagnostic and Statistical Manual of Mental Disorders--Fourth Edition (DSM-IV)
             Axis I disorder other than AD

          -  Previous imaging results not consistent with the diagnosis of AD

          -  Modified Hachinski Ischemia Score greater than 4

          -  Evidence of other neurologic disorders

          -  Clinically significant systemic disease

          -  A known or suspected history of alcohol or drug abuse in the past 5 years

          -  Taking excluded medication

          -  Previous treatment with commercial memantine</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>265</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Forest Investigative Site - East Gosford</hospital>
    <hospital>Forest Investigative Site - Hornsby</hospital>
    <hospital>Forest Investigative Site - Kogarah</hospital>
    <hospital>Forest Investigative Site - Newcastle</hospital>
    <hospital>Forest Investigative Site - Randwick</hospital>
    <hospital>Forest Investigative Site - Chermside</hospital>
    <hospital>Forest Investigative Site - Toowoomba</hospital>
    <hospital>Forest Investigative Site - Adelaide</hospital>
    <hospital>Forest Investigative Site - Woodville</hospital>
    <hospital>Forest Investigative Site - Box Hill</hospital>
    <hospital>Forest Investigative Site - Frankston</hospital>
    <hospital>Forest Investigative Site - Heidelberg West</hospital>
    <hospital>Forest Investigative Site - Kew</hospital>
    <hospital>Forest Investigative Site - Perth</hospital>
    <postcode>2250 - East Gosford</postcode>
    <postcode>2077 - Hornsby</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2300 - Newcastle</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>4032 - Chermside</postcode>
    <postcode>4350 - Toowoomba</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5011 - Woodville</postcode>
    <postcode>3182 - Box Hill</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3081 - Heidelberg West</postcode>
    <postcode>3101 - Kew</postcode>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>North Shore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Timaru</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>E. Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>KZ-Natal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>W. Cape</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Forest Laboratories</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of this study is to evaluate the effect of memantine versus placebo on
      functional communication in patients with Alzheimer's Disease</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00469456</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>F C Potocnik</name>
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>